Scholar Rock (SRRK) Competitors

Dr. Reddy's Laboratories (NYSE:RDY) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Do analysts rate RDY or SRRK?

Dr. Reddy's Laboratories presently has a consensus price target of $17.00, indicating a potential upside of 21.43%. Scholar Rock has a consensus price target of $42.67, indicating a potential upside of 29.65%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings & valuation, RDY or SRRK?

Dr. Reddy's Laboratories has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$311.31B	0.04	$668M	$0.63	22.22
Scholar Rock	$33.19M	94.06	-$165.79M	-$2.45	-13.43

Does the media refer more to RDY or SRRK?

In the previous week, Scholar Rock had 14 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 23 mentions for Scholar Rock and 9 mentions for Dr. Reddy's Laboratories. Scholar Rock's average media sentiment score of 1.21 beat Dr. Reddy's Laboratories' score of 1.17 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	18 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in RDY or SRRK?

Dr. Reddy's Laboratories received 152 more outperform votes than Scholar Rock when rated by MarketBeat users. However, 66.27% of users gave Scholar Rock an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote.

Company	Underperform	Outperform
Dr. Reddy's Laboratories	Outperform Votes 321 59.33%	Underperform Votes 220 40.67%
Scholar Rock	Outperform Votes 169 66.27%	Underperform Votes 86 33.73%

Do institutionals and insiders hold more shares of RDY or SRRK?

3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more risk and volatility, RDY or SRRK?

Dr. Reddy's Laboratories has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Is RDY or SRRK more profitable?

Dr. Reddy's Laboratories has a net margin of 17.25% compared to Scholar Rock's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	17.25%	17.87%	12.32%
Scholar Rock	N/A	-145.60%	-91.83%

Summary

Scholar Rock beats Dr. Reddy's Laboratories on 10 of the 18 factors compared between the two stocks.